Indivior PLC $INDV Stock Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA raised its stake in Indivior PLC (NASDAQ:INDV) by 13.6% in the third quarter, HoldingsChannel.com reports. The fund owned 328,777 shares of the company’s stock after purchasing an additional 39,319 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Indivior were worth $12,017,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Guidance Capital Inc. acquired a new stake in shares of Indivior during the third quarter valued at $782,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Indivior in the 3rd quarter valued at about $216,000. Profund Advisors LLC raised its stake in Indivior by 268.8% in the 3rd quarter. Profund Advisors LLC now owns 49,650 shares of the company’s stock valued at $1,780,000 after purchasing an additional 36,188 shares during the last quarter. Vise Technologies Inc. raised its stake in Indivior by 33.0% in the 3rd quarter. Vise Technologies Inc. now owns 9,298 shares of the company’s stock valued at $333,000 after purchasing an additional 2,306 shares during the last quarter. Finally, State of Wyoming lifted its holdings in Indivior by 75.5% in the 3rd quarter. State of Wyoming now owns 6,505 shares of the company’s stock valued at $233,000 after purchasing an additional 2,799 shares in the last quarter. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CAO Woodrow D. Anderson purchased 1,500 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were bought at an average price of $35.69 per share, with a total value of $53,535.00. Following the completion of the purchase, the chief accounting officer directly owned 27,638 shares in the company, valued at approximately $986,400.22. This trade represents a 5.74% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 0.74% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Friday, October 2nd. Barclays upped their price objective on shares of Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a research note on Wednesday, October 28th. Wall Street Zen downgraded shares of Indivior from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 31st. Craig Hallum restated a “buy” rating and set a $53.00 target price on shares of Indivior in a research report on Tuesday, August 4th. Finally, Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $46.40.

Indivior Price Performance

NASDAQ INDV opened at $28.21 on Friday. The company has a market cap of $3.33 billion, a P/E ratio of 7.88 and a beta of 0.84. Indivior PLC has a 12 month low of $27.68 and a 12 month high of $42.81. The company has a 50-day moving average of $34.37 and a 200-day moving average of $35.52.

Indivior (NASDAQ:INDV) last released its earnings results on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.26. Indivior had a net margin of 32.75% and a negative return on equity of 418.04%. The business had revenue of $356.00 million for the quarter, compared to analysts’ expectations of $329.35 million. As a group, equities research analysts anticipate that Indivior PLC will post 3.66 EPS for the current year.

Indivior Dividend Announcement

The business also recently declared a special dividend, which was paid on Friday, November 6th. Investors of record on Friday, October 30th were given a dividend of $8.13 per share. The ex-dividend date of this dividend was Tuesday, November 3rd.

Indivior Profile

Indivior is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment. The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.